What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes?

被引:13
作者
Hillman, N
Herranz, L
Grande, C
Vaquero, PM
Pallardo, LF
机构
[1] Hosp Univ La Paz, Dept Endocrinol & Nutr, Unidad Diabet, Madrid 28046, Spain
[2] Hosp Univ La Paz, Dept Biochem, Madrid 28046, Spain
关键词
Type; 1; diabetes; glucose profiles; HbA(1c); preprandial glycaemia; postprandial glycaemia;
D O I
10.1111/j.1464-5491.2004.01184.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the relative contribution of blood glucose levels at different rime points of the day to HbA(1c) in Type 1 diabetes. Methods Consecutive home blood glucose records (n = 146) from 71 Type 1 diabetic patients who were on an intensive diabetes therapy programme were examined. Each home blood glucose record included six daily blood glucose profiles over 2 months. The relationship between glycaemic values at each time point and HbA(1c) measured at the end of each record period was analysed. Results Significant linear correlations were found between HbA(1c) and glycaemia at each time point of the clay (ranged from 0.413 to 0.593), the strongest being with predinner glycaemia (r = 0.593; P = 0.000). Total daily glycaemia, mean preprandial and mean postprandial glycaemia were also significant and linearly correlated with HbA(1c) (r = 0.701; r = 0.686; r = 0.620, respectively; P < 0.0001.). Multiple linear regression analysis showed that predinner, prebreakfast and post-breakfast glycaemia correlated significantly and independently with HbA(1c). The model accounted for 47.8% of the variance in HbA(1c). Conclusions Our study shows that among individual time points, prebreakfast and predinner are those with more influence on HbA(1c) in Type 1 diabetes and, to a lesser extent, post breakfast. It also confirms that preprandial glycaemia better predicts overall glycaemic control in Type 1 diabetes than postprandial glycaemia.
引用
收藏
页码:468 / 470
页数:3
相关论文
共 9 条
[1]   Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes -: Implications for treatment and monitoring of metabolic control [J].
Bonora, E ;
Calcaterra, F ;
Lombardi, S ;
Bonfante, N ;
Formentini, G ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2001, 24 (12) :2023-2029
[2]   Is MAI1c influenced more strongly by preprandial postprandial glycemia in type I diabetes? [J].
Hillman, N ;
Herranz, L ;
Grande, C ;
Villaroel, A ;
Pallardo, LF .
DIABETES CARE, 2002, 25 (06) :1100-1101
[3]  
Kahn R, 2001, DIABETES CARE, V24, P775
[4]  
Lafrance L, 1998, DIABETIC MED, V15, P972, DOI 10.1002/(SICI)1096-9136(1998110)15:11<972::AID-DIA704>3.0.CO
[5]  
2-2
[6]   PREPRANDIAL BLOOD-GLUCOSE VALUES - INFLUENCE ON GLYCEMIC RESPONSE STUDIES [J].
NIELSEN, PH ;
NIELSEN, GL .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1989, 49 (06) :1243-1246
[7]   Defining the relationship between plasma glucose and HbA1c -: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial [J].
Rohlfing, CL ;
England, JD ;
Wiedmeyer, HM ;
Tennill, A ;
Little, RR ;
Goldstein, DE .
DIABETES CARE, 2002, 25 (02) :275-278
[8]   THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
SHAMOON, H ;
DUFFY, H ;
FLEISCHER, N ;
ENGEL, S ;
SAENGER, P ;
STRELZYN, M ;
LITWAK, M ;
WYLIEROSETT, J ;
FARKASH, A ;
GEIGER, D ;
ENGEL, H ;
FLEISCHMAN, J ;
POMPI, D ;
GINSBERG, N ;
GLOVER, M ;
BRISMAN, M ;
WALKER, E ;
THOMASHUNIS, A ;
GONZALEZ, J ;
GENUTH, S ;
BROWN, E ;
DAHMS, W ;
PUGSLEY, P ;
MAYER, L ;
KERR, D ;
LANDAU, B ;
SINGERMAN, L ;
RICE, T ;
NOVAK, M ;
SMITHBREWER, S ;
MCCONNELL, J ;
DROTAR, D ;
WOODS, D ;
KATIRGI, B ;
LITVENE, M ;
BROWN, C ;
LUSK, M ;
CAMPBELL, R ;
LACKAYE, M ;
RICHARDSON, M ;
LEVY, B ;
CHANG, S ;
HEINHEINEMANN, M ;
BARRON, S ;
ASTOR, L ;
LEBECK, D ;
BRILLON, D ;
DIAMOND, B ;
VASILASDWOSKIN, A ;
LAURENZI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :977-986
[9]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853